Planned Parenthood plans to withdraw from Title X program, amid looming Trump Administration rule changes; a new cure accepted by the FDA for a deadly strain of tuberculosis has been found to have a 90% success rate in a patient trial; opioid distribution to patients has began to change amongst doctors with new recommendations based around set prescribing levels.
Planned Parenthood announced Wednesday it will soon leave Title X, the federal family planning program, barring a court decision to delay Trump administration rules that bar clinics from referring patients for abortions, Associated Press reported. HHS stated the agency's willingness to accommodate clinics that are making efforts to comply with upcoming rule changes, but Planned Parenthood's spokeswoman Erica Sackin stated the organization’s intent to leave the program, due to regulations set to take effect September 18.A small trial consisting of 109 patients has shown a groundbreaking success rate of 90% against a deadly strain of drug-resistant tuberculosis. This particular XDR strain is involved in about 30,000 cases in over 100 countries, with a cure rate of only 34%. The New York Times reported that the FDA has endorsed the new approach by approving the use of 3 pills: pretomanid, bedaquiline, and linezolid. The treatment can soon come into use worldwide. Narcotic prescriptions have been reduced by nearly one-third since October 2017, after growing concern about the opioid crisis, Kaiser Health News reports. Surgeons stated the transition of narcotic prescriptions have changed dramatically since the beginning of their careers as there was little or no information recommended to them about pill distribution to patients after procedures. The Michigan OPEN guidelines now recommends for no more than 10 pills, equivalent to 5 mg of oxycodone, for an operation such as a minor hernia repair, as opposed to the 29 pills prescribed in the past.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More